CA3101421C - Prodrugs of fulvestrant - Google Patents

Prodrugs of fulvestrant Download PDF

Info

Publication number
CA3101421C
CA3101421C CA3101421A CA3101421A CA3101421C CA 3101421 C CA3101421 C CA 3101421C CA 3101421 A CA3101421 A CA 3101421A CA 3101421 A CA3101421 A CA 3101421A CA 3101421 C CA3101421 C CA 3101421C
Authority
CA
Canada
Prior art keywords
group
aryl
optionally substituted
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3101421A
Other languages
English (en)
French (fr)
Other versions
CA3101421A1 (en
Inventor
Parva Yogeshchandra Purohit
Pathik Subhashchandra BRAHMKSHATRIYA
Vishalgiri Gunvantgiri GOSWAMI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ki Pharmaceuticals LLC
Original Assignee
Ki Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ki Pharmaceuticals LLC filed Critical Ki Pharmaceuticals LLC
Publication of CA3101421A1 publication Critical patent/CA3101421A1/en
Application granted granted Critical
Publication of CA3101421C publication Critical patent/CA3101421C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3101421A 2018-05-24 2019-05-24 Prodrugs of fulvestrant Active CA3101421C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201821019542 2018-05-24
IN201821019542 2018-05-24
IN201821047939 2018-12-18
IN201821047939 2018-12-18
PCT/IB2019/054315 WO2019224790A2 (en) 2018-05-24 2019-05-24 Prodrugs of fulvestrant

Publications (2)

Publication Number Publication Date
CA3101421A1 CA3101421A1 (en) 2019-11-28
CA3101421C true CA3101421C (en) 2024-06-18

Family

ID=68615936

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3101421A Active CA3101421C (en) 2018-05-24 2019-05-24 Prodrugs of fulvestrant

Country Status (6)

Country Link
US (1) US20210253626A1 (https=)
EP (1) EP3801553B1 (https=)
JP (2) JP7384903B2 (https=)
AU (1) AU2019274815B2 (https=)
CA (1) CA3101421C (https=)
WO (1) WO2019224790A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
EP4061376A4 (en) * 2019-11-24 2024-03-13 Kashiv Biosciences, LLC Prodrugs of fulvestrant
TW202146405A (zh) * 2020-02-25 2021-12-16 日商大日本住友製藥股份有限公司 Cdk9抑制劑前體藥物及內封其之脂質體
WO2022034587A1 (en) * 2020-08-10 2022-02-17 Tnik Therapeutics Ltd Traf2- AND Nck-INTERACTING KINASE (TNIK) INHIBITORS AND USES THEREOF
WO2023027032A1 (ja) * 2021-08-23 2023-03-02 住友ファーマ株式会社 自己分解型ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
AU2022377397A1 (en) * 2021-10-29 2024-06-13 Kashiv Biosciences, Llc Inectable pharmaceutical composition for treatment of breast cancer
CN117957238A (zh) * 2021-12-06 2024-04-30 江苏亚虹医药科技股份有限公司 氟维司群衍生物及其制备方法和医药用途
EP4444318A4 (en) * 2021-12-06 2026-01-28 Amneal Pharmaceuticals Llc COMPOUNDS FOR CANCER TREATMENT
CN119751533B (zh) * 2025-03-10 2026-01-13 山东大学 一种基于雌甾三烯结构的雌激素受体蛋白靶向降解嵌合体衍生物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CA2909418A1 (en) * 2013-04-18 2014-10-23 Xi'an Libang Pharmaceutical Technology Co., Ltd. Ester derivative of 7-.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)n onyl]-estra-1,3,5(10)-triene-3,17.beta.-diol having anticancer activity and preparation method thereof
CN103421069A (zh) 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用
US10112962B2 (en) 2014-07-02 2018-10-30 Xavier University Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2019050850A1 (en) * 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
CN108159055A (zh) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Also Published As

Publication number Publication date
EP3801553A2 (en) 2021-04-14
WO2019224790A3 (en) 2020-01-16
JP7653092B2 (ja) 2025-03-28
JP7384903B2 (ja) 2023-11-21
EP3801553B1 (en) 2026-03-25
CA3101421A1 (en) 2019-11-28
JP2021525278A (ja) 2021-09-24
WO2019224790A2 (en) 2019-11-28
JP2024016210A (ja) 2024-02-06
EP3801553A4 (en) 2022-04-27
AU2019274815B2 (en) 2024-11-07
AU2019274815A1 (en) 2021-01-21
US20210253626A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CA3101421C (en) Prodrugs of fulvestrant
JP6700293B2 (ja) リルゾールプロドラッグおよびそれらの使用
KR20210052331A (ko) Ezh2 저해제　및　e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물
AU2008250254B2 (en) New cyclic peptide compounds
BR112015001545B1 (pt) Composto, composição farmacêutica, e, uso de um composto
EA023578B1 (ru) C28-амины c3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
BRPI0709283A2 (pt) derivados de n-hidroxi-3- (4-{3-fenil-s-oxo-propenil} -fenil) - acrilamida e compostos relacionados a estes, tais como inibidores de histona desacetilase para o tratamento de cáncer
JPH06271549A (ja) ピペラジン誘導体
BR112019013001A2 (pt) inibidores de histona desacetilase
ES2376399T3 (es) Compuestos de piperazinona como agentes antitumorales y anticancer�?genos.
AU2021336518A1 (en) Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof
US20210387990A1 (en) Method for producing dimethoxybenzene compound
JP2023503898A (ja) フルベストラントのプロドラッグ
NZ240167A (en) Heterocyclically substituted thiol amide derivatives; medicaments, preparation, and use thereof
ES2371133T3 (es) Una nueva clase de inhibidores de histona desacetilasa.
CZ20011506A3 (cs) Omega-amidy N-arylsulfonylaminokyselin, způsob jejich přípravy a léčivo, které je obsahuje
AU2018448845B2 (en) Method for producing dimethoxybenzene compound
RU2469020C1 (ru) (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения
AU2009212072A1 (en) Arylmethylidene heterocycles as novel analgesics
WO2005051901A1 (en) Anti-cancer agents
CA3016086A1 (en) Compounds for the inhibition of cyclophilins and uses thereof
CA3259556A1 (en) COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION
EP4463450A1 (en) Fused heteroaryl hydroxamates as sting agonists
AU2011311847A1 (en) Method of preparation of antiviral compounds and useful intermediates thereof
WO2021156811A1 (en) Novel processes for preparation of tezacaftor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220519

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20250423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250423

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250527

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250527

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250725

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251114

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260305

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260309

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260408